Docquier, A., Garcia, A., Savatier, J., Boulahtouf, A., Bonnet, S., Bellet, V., Busson, M., Jalaguier, S., Margeat, E., Royer, C., Balaguer, P. and Cavailles, V. (2013) Negative regulation of estrogen signaling by ERbeta and RIP140 in ovarian cancer cells. Molecular Endocrinology, 27, 1429-1441.

has been cited by the following article:

• TITLE: Dialogue between estrogen receptor and E2F signaling pathways: The transcriptional coregulator RIP140 at the crossroads

  AUTHORS: Marion Lapierre, Aurélie Docquier, Audrey Castet-Nicolas, Stéphan Jalaguier, Catherine Teyssier, Patrick Augereau, Vincent Cavaillès

  KEYWORDS: RIP140; E2F Transcription Factors; Estrogen Receptors; Gene Expression; Cell Proliferation; Breast Cancer; Endocrine Therapies

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.4 No.10B, October 8, 2013

  ABSTRACT: Estrogen receptors and E2F transcription factors are the key players of two nuclear signaling pathways which exert a major role in oncogenesis, particularly in the mammary gland. Different levels of dialogue between these two pathways have been deciphered and deregulation of the E2F pathway has been shown to impact the response of breast cancer cells to endocrine therapies. The present review focuses on the transcriptional coregulator RIP140/NRIP1 which is involved in several regulatory feed-back loops and inhibitory cross-talks between different nuclear signaling pathways. RIP140 regulates the transactivation potential of estrogen receptors and E2Fs and is also a direct transcriptional target of these transcription factors. Published data highlight the complex regulation of RIP140 expression at the transcriptional level and its potential role in transcription cross-talks. Indeed, a subtle regulation of RIP140 expression levels has important consequences on other transcription networks targeted by this coregulator. Another level of regulation implies titration mechanisms by which activation of a pathway leads to sequestration of the RIP140 protein and thus impinges other gene regulatory circuitries. Altogether, RIP140 occupies a place of choice in the dialogue between nuclear receptors and E2Fs, which could be highly relevant in various human pathologies such as cancer or metabolic diseases.